A year-and-a-half after the In-Custody Death Review Division was created within a state agency, the office has yet to obtain ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

SK Hynix’s clever 5-bit flash could revolutionize SSD density while keeping costs stubbornly high for users ...

The mini review brings together emerging evidence showing that glial cells actively influence disease progression and ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Knowable Magazine reports on advancements in pancreatic cancer treatment, including new drugs, vaccines, and early diagnostic technologies promising improved survival rates.

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...

T cells are central mediators of autoimmune disease pathogenesis, yet their functional states are not defined solely by antigen recognition or canonical ...

A Las Vegas hospital has achieved a major milestone as staff celebrates the completion of its 100th stem cell transplant.

The Trump administration announced Thursday that human fetal tissue derived from abortions can no longer be used in research ...